alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                       1,760,636
<INT-BEARING-DEPOSITS>                         367,304
<FED-FUNDS-SOLD>                               226,730
<TRADING-ASSETS>                               126,540
<INVESTMENTS-HELD-FOR-SALE>                  9,246,790
<INVESTMENTS-CARRYING>                          97,607
<INVESTMENTS-MARKET>                            99,336
<LOANS>                                     22,311,258
<ALLOWANCE>                                    308,890
<TOTAL-ASSETS>                              35,800,177
<DEPOSITS>                                  25,461,397
<SHORT-TERM>                                 3,002,660
<LIABILITIES-OTHER>                            514,031
<LONG-TERM>                                  3,723,334
<COMMON>                                         1,574
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   3,072,181
<TOTAL-LIABILITIES-AND-EQUITY>              35,800,177
<INTEREST-LOAN>                              1,771,235
<INTEREST-INVEST>                              590,686
<INTEREST-OTHER>                                30,197
<INTEREST-TOTAL>                             2,392,118
<INTEREST-DEPOSIT>                             931,716
<INTEREST-EXPENSE>                           1,287,858
<INTEREST-INCOME-NET>                        1,104,260
<LOAN-LOSSES>                                   51,154
<SECURITIES-GAINS>                              15,435
<EXPENSE-OTHER>                              1,026,757
<INCOME-PRETAX>                                568,267
<INCOME-PRE-EXTRAORDINARY>                     375,303
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   375,303
<EPS-PRIMARY>                                     2.45
<EPS-DILUTED>                                     2.41
<YIELD-ACTUAL>                                    3.56
<LOANS-NON>                                    132,713
<LOANS-PAST>                                    28,998
<LOANS-TROUBLED>                                 5,950
<LOANS-PROBLEM>                                 90,834
<ALLOWANCE-OPEN>                               284,165
<CHARGE-OFFS>                                   64,866
<RECOVERIES>                                    22,782
<ALLOWANCE-CLOSE>                              308,890
<ALLOWANCE-DOMESTIC>                           308,890
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                         73,127
        

</TABLE>
EXHIBIT 31.2




CERTIFICATIONS


I, Anthony E. Applebaum, certify that:





1.  I have reviewed this quarterly report on Form 10-Q of Mera Pharmaceuticals, Inc.;





2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;





3.  Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;





4.  The Company's other certifying officers and I, are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:





a)
designed such disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;





b)
evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and





c)
presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;





5.  The Company's other certifying officers and I have disclosed, based on our most recent evaluation, to the Company's auditors and the audit committee of Company's board of directors (or persons performing the equivalent functions):





a)
all significant deficiencies in the design or operation of internal controls which could adversely affect the Company’s ability to record, process, summarize and report financial data and have identified for the Company's auditors any material weaknesses in internal controls; and





b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls; and





6.  The Company's other certifying officers and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.





Date:  June 14, 2010





/s/ Anthony E. ApplebaumAnthony E. ApplebaumPrincipal Financial and Accounting Officer
Exhibit
23.1




CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM





We have
issued our report dated March 6, 2009, accompanying the consolidated financial
statements included in the Annual Report of United Capital Corp. and
Subsidiaries on Form 10-K for the year ended December 31, 2008.  We
hereby consent to the incorporation by reference of said report in the
Registration Statements of United Capital Corp. on Form S-8 (Registration Nos.
33-28045, 33-65140, 333-28395, 333-57873 and 333-98645).











/s/ Holtz Rubenstein
Reminick
LLP


HOLTZ
RUBENSTEIN REMINICK LLP








Melville,
New York


March 26,
2009
**EXHIBIT
      32.1**




**Certification
      Pursuant to**


**18
      U.S.C. Section 1350, as Adopted Pursuant to**


**Section
      906 of the Sarbanes-Oxley Act of 2002**




In
      connection with the Quarterly Report on Form 10-Q of AHPC Holdings, Inc. (the
      “Company”) for the quarter ended December 31, 2005 as filed with the Securities
      and Exchange Commission on the date hereof (the “Report”), Alan E. Zeffer, as
      Chief Executive Officer of the Company, and Deborah J. Bills, as Chief Financial
      Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section
      1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      that:




(1) The
      Report fully complies with the requirements of Section 13(a) of the Securities
      Exchange Act of 1934; and




(2) the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.




/s/
                Alan E.
                Zeffer
              Name:Alan
                E. Zeffer
              Title:Chief
                Executive Officer
              Date:February
                14, 2006/s/
                Deborah J.
                Bills
              Name:Deborah
                J. Bills
              Title:Chief
                Financial Officer
              Date:February
                14, 2006





This
      certification is made solely for purposes of 18 U.S.C. Section 1350 subject
      to
      the knowledge standard contained therein, and not for any other
      purpose.
```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4197 Introduced in House (IH)]

108th CONGRESS
  2d Session
                                H. R. 4197

        To suspend temporarily the duty on othro nitro aniline.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 22, 2004

  Mr. Bonner introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
        To suspend temporarily the duty on othro nitro aniline.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SUSPENSION OF DUTY ON OTHRO NITRO ANILINE.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following:

``      9902.34.24       Othro nitro        Free         No Change        No Change        On or Before 12/  ''.
                         aniline (CAS No.                                                   31/2007
                         88-74-4)
                         (provided for in
                         subheading
                         2921.42.90)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
I 

108TH CONGRESS 

2D SESSION H. R. 4305 

To amend title 18, United States Code, to increase protections for children 

from obscene material on the Internet. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 6, 2004 

Mr. BRADY of Pennsylvania introduced the following bill; which was referred 

to the Committee on the Judiciary 

A BILL 

To amend title 18, United States Code, to increase protections for children from obscene material on the Internet. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Children’s Online Safe5 ty Act of 2004’’. 
2 

•HR 4305 IH 

1 SEC. 2. INCREASED PROTECTION FOR CHILDREN FROM OB2 SCENE MATERIAL ON THE INTERNET. 

3 Subsections (b) and (c) of section 2252B of title 18, 

4 United States Code, are each amended by inserting ‘‘or 

5 meta tag’’ after ‘‘domain name’’. 

Æ
<PAGE>   1


                                                                    EXHIBIT 99.3


[XENOMETRIX LOGO]                                                         NEWS


--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE                              Xenometrix, Inc.
                                                   2425 North 55th Street
Contact: Stephen J. Sullivan, C.E.O.               Boulder, CO 80301
         (303) 447-1773 ext.149                    Telephone:   (303) 447-1773
                                                   Facsimile:     (303) 447-1758



                  XENOMETRIX RECEIVES EXTENSION ON BRIDGE NOTES

BOULDER, CO., MAY 28, 1998 - Xenometrix, Inc. (OTC BB: XENO), announced today
that it has received a one month extension on the $1,500,000 bridge notes that
were due May 25th. The new due date is June 25, 1998.

At May 15, 1998, the Company had cash and cash equivalents of approximately
$330,000. The Company estimates that its resources will be sufficient to meet
its operating needs through June 30, 1998. In the event the Company does not
repay the notes or secure an extension to the due date and obtain additional
financing, the Company will evaluate other options including, but not limited to
further curtailing or suspending its operations.

Xenometrix is a biotechnology company with proprietary gene expression profiling
technology and genotoxicology technology used to help pharmaceutical, chemical
and biotechnology companies to accelerate the selection of the most promising
drug and chemical leads.

Except for the historical information contained herein, this release contains
forward-looking statements relating to future financial results or business
expectations. Business plans may change as circumstances warrant. Actual results
could differ materially as a result of risk-related factors over which the
Company has no control. Such factors include, but are not limited to those
discussed in "Business," "Risk Factors," and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in the Company's Form
10-KSB filed with the Securities and Exchange Commission for the year ended June
30, 1997.

                                       ###
Order entered November 1 4 , 2022

In The 

### Court of Appeals Fifth District of Texas at Dallas
No. 05
- 22
- 00163
- CV SALLY TYE F/K/A SALLY S. SHUFFIELD, INDIVIDUALLY AND AS CO
TRUSTEE OF THE SHUFFIELD LIVI NG TRUST , Appellant
V. RODNEY M. SHUFFIELD, INDIVIDUALLY AND AS CO
- TRUSTEE OF

THE SHUFFIELD LIVING TRUST , Appellee On Appeal from the 380th Judicial District Court

Collin County, Texas Trial Court Cause No. 380
- 02071
- 2020

O RDER Before Chief Justice Bur ns, Justice Molberg, and Justice Pedersen, III Before the Court are appellee’s October 17, 2022 motion to dismiss the appeal and appellant’s November 4, 2022 motion to extend time to file her reply
brief

. We GRANT the extension motion and ORDER the brief be filed no later
than December 6, 2022. We DEFER to submission the motion to dismiss.

/s/ KEN MOLBERG JUSTICE
<TABLE> <S> <C>


<ARTICLE>                     5

<LEGEND>
The  schedule  contains  summary  financial   information   extracted  from  the
consolidated  balance  sheets  and  consolidated  statements  of  income  and is
qualified in its entirety by reference to such financial statements.
</LEGEND>

       
<S>                                           <C>
<PERIOD-TYPE>                                  3-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-END>                                   MAR-31-1997
<CASH>                                             971,635
<SECURITIES>                                             0
<RECEIVABLES>                                      270,088
<ALLOWANCES>                                             0
<INVENTORY>                                        271,364
<CURRENT-ASSETS>                                         0
<PP&E>                                             910,695
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                   2,522,565
<CURRENT-LIABILITIES>                                    0
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                                 0
<OTHER-SE>                                       2,111,992
<TOTAL-LIABILITY-AND-EQUITY>                     2,522,565
<SALES>                                             42,546
<TOTAL-REVENUES>                                   308,672
<CGS>                                                    0
<TOTAL-COSTS>                                      238,427
<OTHER-EXPENSES>                                    78,729
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                     70,245
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                 70,245
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                        70,246
<EPS-PRIMARY>                                         0.57
<EPS-DILUTED>                                         0.57
        


</TABLE>
<PAGE>   1
                                                                    Exhibit 23.2


                       CONSENT OF INDEPENDENT ACCOUNTANTS


As independent public accountants, we hereby consent to the incorporation by
reference in this registration statement on Form S-8 of MCI WorldCom, Inc. of
our report dated February 14, 1996, on our audits of the consolidated financial
statements of MFS Communications Company, Inc. as of December 31, 1995 and 1994
and for each of the three and two years in the period ended December 31, 1995,
which reports are included in WorldCom, Inc.'s Current Report on Form 8-K/A
dated August 25, 1996 (as amended on November 4, 1996 and December 19, 1997).



PricewaterhouseCoopers LLP
Omaha, Nebraska
September 14, 1998
Exhibit 99.1

Annual CEO Certification(Section
303A.12(a))

As the Chief Executive Officer of
Mestek, Inc.,

and as required by Section 303A.12(a)
of the New York Stock Exchange Listed Company Manual, I hereby certify that as of the date
hereof I am not aware of any violation by the Company of NYSEs Corporate Governance
listing standards, other than has been notified to the Exchange pursuant to Section
303A.12(b) and disclosed as an attachment hereto.

|Date: March 31, 2005 | By:  /s/ John E. Reed          
|-------------------- | -------------------------------
|                     | Name:  John E. Reed            
|                     | Title:  Chief Executive Officer
EXHIBIT 4.36


 


Non-executive director
appointment letter – Mr John G Thorn


 


The Non-executive director appointment letter of Mr John G Thorn is
incorporated by reference to National Australia Bank Limited’s Annual Report on
Form 20-F for the fiscal year ended September 30, 2004 as filed with
the Commission on January 20, 2005
#### J. P. McCullom *v.*P. H. Cochran.

Pleading — Answer—Reply—Admission—Production of Choses in Action.

"Where plaintiff’s reply to 'defendant’s aniswer and counter-claim admits that plaintiff has in his possession choses in action to the value of ¡¡>250, which had not been accounted for, he must produce them, or the court will credit defendant with the amount, in the absence of a showing that they can not be used as a set-off.

Equity — Recital in Decree — Proof.

The mere recital in a decree in equity that the case was heard upon the pleadings, proof, and exhibits, is no evidence that parol testimony was introduced and heard in the case:

APPEAL PROM LOUISVILLE' CHANCERY COURT.

December 16, 1872.

Opinion by

Judge Pryor:

This suit was transferred from the common pleas court to the Louisville chancery court and tried in equity. The reply of the appellee to the answer and counter claim of the appellant in the suit first instituted in that court admits that the choses in action 'left in appellee’s possession were of the value of two' hundred and fifty dollars. The choses in action or their value have not heen accounted for in any way by the appellee. Although he does not ad*112mit that these claims were left with him to' pay this identical debt, still, he does admit, that they were left *to*pay the debts of Overton and we see no reason why he should not be made to account.

*Caldwell, for appellant.*

*Thompson & Booth, for appellee.*

His response amounts to nothing. He must show his hand, by extinguishing the claims or making some proof showing the disposition he has made of these accounts. Admitting as he does that he has $250 of dioses in action that were- good, he must either produce them, or the court, in the absence of testimony showing that they can not be used as a set-off in this case, must credit the appellant for the amount. The judgment of the court below is reversed and cause remanded for further proceedings consistent with this opinion. There is nothing in the record showing that the court heard proof in the court below. The mere recitation in. a judgment in equity that the case is heard upon the pleadings, proof and' exhibits is no evidence that parol testimony was introduced and heard in the case.
I 

108TH CONGRESS 

2D SESSION H. R. 4478 

To provide for an additional temporary extension of programs under the 

Small Business Act and the Small Business Investment Act of 1958 

through July 23, 2004, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 2, 2004 

Mr. MANZULLO introduced the following bill; which was referred to the 

Committee on Small Business 

A BILL 

To provide for an additional temporary extension of programs under the Small Business Act and the Small 

Business Investment Act of 1958 through July 23, 2004, 

and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ADDITIONAL TEMPORARY EXTENSION OF AU4 THORIZATION OF PROGRAMS UNDER SMALL 

5 BUSINESS ACT AND SMALL BUSINESS INVEST6 MENT ACT OF 1958. 

7 The authorization for any program, authority, or pro8 vision, including any pilot program, that was extended 
2 

•HR 4478 IH 

1 through June 4, 2004, by section 1 of Public Law 108– 

2 217 is further extended through July 23, 2004, under the 

3 same terms and conditions. 

4 SEC. 2. TECHNICAL AMENDMENT. 

5 Section 2 of Public Law 108–205 is amended by 

6 striking ‘‘October 1, 2003’’ and inserting ‘‘March 15, 

7 2004’’. The amendment made by the preceding sentence 

8 shall take effect as if included in the enactment of the 

9 section to which it relates. 

Æ